SCHEMBL6930419

SCHEMBL6930419

[O-][S+](Sc1ccccc1)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.39
HPGD P15428 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MGLL Q99685 1/20 0.39
HSD17B10 Q99714 1/20 0.39
ALDH1A1 P00352 1/20 0.35
MAPK1 P28482 1/20 0.35
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9443770 0.87 ALDH1A1 (0.38) MAPTHPGDSMN1; SMN2MGLLHSD17B10
SCHEMBL9443817 0.85 TSHR (0.39) MAPTHPGDSMN1; SMN2MGLLHSD17B10
SCHEMBL9443803 0.85 LMNA (0.39) MAPTHPGDSMN1; SMN2ALDH1A1TSHR
SCHEMBL9443793 0.85 ALDH1A1 (0.39) MAPTHPGDSMN1; SMN2MGLLHSD17B10
SCHEMBL9443831 0.85 ACHE (0.39) MAPTHPGDSMN1; SMN2MGLLHSD17B10
SCHEMBL9443804 0.85 NR1H2 (0.39) MAPTHPGDHSD17B10ALDH1A1
SCHEMBL9443806 0.83 KMT2A (0.37) MAPTHPGDSMN1; SMN2ALDH1A1
SCHEMBL9443807 0.82 ALDH1A1 (0.36) MAPTSMN1; SMN2ALDH1A1MAPK1TSHR
SCHEMBL9443838 0.82 TSHR (0.35) MAPTALDH1A1MAPK1TSHR
SCHEMBL10525723 0.80 CA4 (0.45) MAPTSMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240374535-A1 COMPOSITIONS AND METHODS FOR TREATING BIOFILM DISORDERS AND INFECTIONS AHV International B.V. (NL) 2024-11-14 US disclosed
CN-114583264-B Electrolyte additive, electrolyte and lithium ion battery 比亚迪股份有限公司 2024-09-10 CN disclosed
CN-114583264-A Electrolyte additive, electrolyte and lithium ion battery 比亚迪股份有限公司 2022-06-03 CN disclosed
CN-111918899-A Cured product of resin composition, laminate, and resin composition 日本板硝子株式会社 2020-11-10 CN disclosed
CN-110885401-A Copolymer, curable resin composition containing same, and cured product thereof 株式会社大赛璐 2020-03-17 CN disclosed
CN-106986803-A Cationic sulfoxide intermediate, polyarylene sulfide monomer and preparation method of polyarylene sulfide 财团法人工业技术研究院 2017-07-28 CN disclosed
WO-2014210132-A2 VALENCY DEPENDENT BIOACTIVE HYDROXYAPATITE-BINDING DENDRONS THE UNIVERSITY OF AKRON (US) 2014-12-31 WO disclosed
US-20030232994-A1 Bicyclic thiophene derivatives and combinatorial libraries thereof LION BIOSCIENCE AG (DE) 2003-12-18 US disclosed
EP-0686160-A4 SOLUTION AND SOLID-PHASE FORMATION OF GLYCOSIDIC LINKAGES UNIV PRINCETON (US) 2003-03-12 EP disclosed
US-6194393-B1 A GLYCOSIDE CONTAINING AN ANOMERIC SULFOXIDE AND NUCLEOPHILIC FUNCTIONAL GROUPS AND HAVING POTENTIAL GLYCOSYL ACCEPTING/DONATING CHARACTERISTICS AND AN ACTIVATING AGENT; RAPID CONSTRUCTION OLIGOSACCHARIDES; GLYCOSYLATION; LIBRARY THE TRUSTEES OF PRINCETON UNIVERSITY 2001-02-27 US disclosed
US-5700916-A INTERMEDIATES FOR FORMING OLIGOSACCHARIDES, INCLUDING 4-HYDROXYTHIOPHENYL-/2-AZIDO-2-DEOXYGLUCO/PYRANOSIDE TRUSTEES OF PRINCETON UNIVERSITY (US) 1997-12-23 US disclosed
US-5639866-A EXPOSING GLYCOSYL ACCEPTOR BOUND TO SOLID SUPPORT TO GLYCOSIDE HAVING ACTIVATED ANOMERIC SULFOXIDE GROUP, FORMING GLYCOSIDIC BOND PRINCETON UNIVERSITY (US) 1997-06-17 US disclosed
US-5635612-A Method of forming multiple glycosidic linkages in a single step THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1997-06-03 US disclosed
EP-0686160-A1 SOLUTION AND SOLID-PHASE FORMATION OF GLYCOSIDIC LINKAGES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1995-12-13 EP disclosed
WO-1994019360-A1 SOLUTION AND SOLID-PHASE FORMATION OF GLYCOSIDIC LINKAGES THE TRUSTEES OF PRINCETON UNIVERSITY (US) 1994-09-01 WO disclosed
US-5321045-A PAF-induced bronchial obstructions BOEHRINGER MANNHEIM GMBH (DE) 1994-06-14 US disclosed
EP-0299424-B1 Thiosulfinic-acid derivatives, and the use of thiosulfin-acid derivatives for the manufacture of a medicament for the treatment of inflammatory diseases BOEHRINGER MANNHEIM GMBH (DE) 1993-10-20 EP disclosed
EP-0324023-A1 THIOSULPHINIC ACID DERIVATIVES, THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES, AND DRUGS CONTAINING THEM Roche Diagnostics GmbH (DE) 1989-07-19 EP disclosed
WO-1989000422-A2 THIOSULPHINIC ACID DERIVATIVES, THEIR USE IN THE TREATMENT OF INFLAMMATORY DISEASES, AND DRUGS CONTAINING THEM BOEHRINGER MANNHEIM GMBH (DE) 1989-01-26 WO disclosed
EP-0299424-A2 Thiosulfinic-acid derivatives, and the use of thiosulfin-acid derivatives for the manufacture of a medicament for the treatment of inflammatory diseases Roche Diagnostics GmbH (DE) 1989-01-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232994-A1 Bicyclic thiophene derivatives and combinatorial libraries thereof CXCR2, BICRA, CXCR1 MAPT 2743/4885HPGD 3319/4885SMN1; SMN2 4658/4885
US-20240374535-A1 COMPOSITIONS AND METHODS FOR TREATING BIOFILM DISORDERS AND INFECTIONS TST, MYD88, BTK MAPT 3417/4885HPGD 2116/4885SMN1; SMN2 4709/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.